Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

This study has been terminated.
(Based on the results of the Phase 1 data, the company decided not to pursue the development of this drug at this time.)
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ) Identifier:
First received: October 10, 2012
Last updated: July 1, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2014
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)